Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Krzysztof Selmaj, Erik Wallström, Olaf Stüve et al.|The Lancet Neurology|2013

Cited by 233